Elsevier,
The Lancet Public Health, Volume 8, April 2023
This Article supports SDG 3 by analysing several cohorts of people with HIV/HCV co-infection across 6 high-income countries, and identifying that a substantial proportion had not commenced direct-acting antiviral treatment for HCV infection despite unrestricted access. Factors associated with commencement or lack thereof are explored; for example, people with indicators of low engagement with HIV care (eg, not on antiretroviral therapy) were more likely not to have commenced HCV direct-acting antiviral treatment)
Elsevier,
eClinicalMedicine, Volume 58, April 2023
This Article supports SDG 3 by providing the first comprehensive review of the global burden of hepatis B and C in people with tuberculosis, through a systematic review and meta-analysis including 127 studies. The review found a high prevalence of these infections in this patient population, showing the need for routine hepatitis testing at the point of diagnosis of tuberculosis.
Elsevier, The Lancet Global Health, Volume 11, April 2023
Drinking water and sanitation services in high-income countries typically bring widespread health and other benefits to their populations. Yet gaps in this essential public health infrastructure persist, driven by structural inequalities, racism, poverty, housing instability, migration, climate change, insufficient continued investment, and poor planning.
Elsevier,
The Lancet Regional Health - Western Pacific, Volume 33, April 2023
This Article supports Sustainable Development Goal 3 by estimating the incidence and risk factors for vascular cognitive symptoms among first-ever stroke survivors in China, and shows an association of post-stroke cognitive impairment with age, education, and region (western China had higher rates of post-stroke cognitive impairment relative to other regions).
Elsevier,
Lancet Regional Health - Americas, Volume 20, April 2023
This Viewpoint supports Sustainable Development Goal 3 by discussing the effects of the FDA's approval of aducanumab, a treatment for early-stage Alzheimer's disease, despite its limited clinical benefit, as well as the decision of the Centers for Medicare and Medicaid Services to restrict coverage to individuals enrolled in clinical trials. The authors note that these decisions have led to a confusing landscape for patients with Alzheimer's disease.
Elsevier,
Environment International, Volume 174, April 2023
The current review on atmospheric M/NPs is therefore focusing on sampling, sample preparation and identification methods. The approach will enable knowledge gaps to be identified, and recommendations to be made to support standardized and comparable future research
